抗逆转录病毒治疗试验中转换/简化方案的伦理学问题：非劣效还是仅仅是劣效？
The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?
机构信息
Clinical Research Program, Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
出版信息
PLoS Med. 2012;9(7):e1001240. doi: 10.1371/journal.pmed.1001240. Epub 2012 Jul 17.
Abstract
Using the SWITCHMRK and MONET trials as examples, Andrew Carr and colleagues question the ethics and motives of switch or simplification trials of anti-retroviral therapy.
摘要
以 SWITCHMRK 和 MONET 试验为例，Andrew Carr 及其同事对抗逆转录病毒治疗的转换或简化试验的伦理和动机提出了质疑。
相似文献
1
The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?抗逆转录病毒治疗试验中转换/简化方案的伦理学问题：非劣效还是仅仅是劣效？
PLoS Med. 2012;9(7):e1001240. doi: 10.1371/journal.pmed.1001240. Epub 2012 Jul 17.
2
Competing commitments in clinical trials.临床试验中的相互冲突的任务。
IRB. 2009 Sep-Oct;31(5):1-6.
3
Inclusion practice in lung cancer trials.肺癌试验中的纳入标准
Nurs Ethics. 2006 Nov;13(6):649-60. doi: 10.1177/0969733006069699.
4
Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015.2010 - 2015年西班牙HIV感染患者初始抗逆转录病毒治疗未遵循国家指南的原因
Enferm Infecc Microbiol Clin (Engl Ed). 2019 Nov;37(9):580-587. doi: 10.1016/j.eimc.2019.02.007. Epub 2019 Apr 11.
5
Biological, clinical, and ethical advances of placebo effects.安慰剂效应的生物学、临床和伦理进展。
Lancet. 2010 Feb 20;375(9715):686-95. doi: 10.1016/S0140-6736(09)61706-2.
6
The paradoxical placebo.矛盾的安慰剂。
Am J Bioeth. 2009 Dec;9(12):17-20. doi: 10.1080/15265160903242733.
7
Patterns of antiretroviral use in the United States of America: analysis of three observational databases.美国抗逆转录病毒药物的使用模式：对三个观察性数据库的分析
HIV Med. 2003 Jan;4(1):24-32. doi: 10.1046/j.1468-1293.2003.00129.x.
8
Improving China's antiretroviral treatment program: assessing current and future performance using the principals of ethics.改善中国的抗逆转录病毒治疗项目：运用伦理原则评估当前及未来表现。
Chin Med J (Engl). 2009 Jun 5;122(11):1346-51.
9
10
Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults.关于欧盟临床试验指令及涉及无行为能力成年人的医学研究的建议。
Wien Klin Wochenschr. 2006 Apr;118(5-6):183-91. doi: 10.1007/s00508-006-0577-2.
引用本文的文献
1
Beyond Viral Suppression.超越病毒抑制
Open Forum Infect Dis. 2021 Jan 30;8(10):ofab044. doi: 10.1093/ofid/ofab044. eCollection 2021 Oct.
2
Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons.在瑞士HIV阳性患者中，将成功的三联抗逆转录病毒疗法系统性降级为多替拉韦加恩曲他滨或拉米夫定的双联疗法
EClinicalMedicine. 2018 Dec 6;6:21-25. doi: 10.1016/j.eclinm.2018.11.005. eCollection 2018 Dec.
3
Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV.一线方案转换对 HIV 稳定期患者的经济学结局影响
J Manag Care Spec Pharm. 2017 Jul;23(7):725-734. doi: 10.18553/jmcp.2017.16403. Epub 2017 Jun 5.
4
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.用于管理HIV感染患者的双重疗法治疗策略：对初治或经治、病毒学抑制患者的当前证据的系统评价
PLoS One. 2016 Feb 5;11(2):e0148231. doi: 10.1371/journal.pone.0148231. eCollection 2016.
5
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.多替拉韦——关于其治疗HIV的药理学、疗效及安全性的综述
Drug Des Devel Ther. 2015 Jul 7;9:3547-55. doi: 10.2147/DDDT.S84850. eCollection 2015.
6
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.远离利托那韦、阿巴卡韦、替诺福韦和依非韦伦（RATE）——令处方医生和患者担忧的药物：一项可行性研究及开展试验的呼吁。
PLoS One. 2014 Jun 26;9(6):e99530. doi: 10.1371/journal.pone.0099530. eCollection 2014.
7
Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.从司他夫定转换为拉替拉韦对合并HIV/高效抗逆转录病毒治疗相关脂肪代谢障碍综合征（HALS）的HIV感染患者皮下脂肪组织的影响：一项临床与分子研究。
PLoS One. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014.
本文引用的文献
1
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.一项四期、双盲、多中心、随机、安慰剂对照、初步研究，旨在评估将继续出现中枢神经系统不良反应的接受依非韦伦治疗的个体转换为依曲韦林的可行性。
AIDS. 2011 Jan 2;25(1):65-71. doi: 10.1097/QAD.0b013e328341685b.
2
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.在病毒血症得到抑制的稳定 HIV 感染者中，换用拉替拉韦方案与继续使用洛匹那韦/利托那韦方案（SWITCHMRK 1 和 2）：两项多中心、双盲、随机对照试验。
Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12.
3
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.MONET 试验：达芦那韦/利托那韦联合或不联合核苷类逆转录酶抑制剂，用于 HIV RNA 低于 50 拷贝/ml 的患者。
AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.
4
Declaration of Helsinki. Ethical principles for medical research involving human subjects.《赫尔辛基宣言》。涉及人类受试者的医学研究伦理原则。
J Indian Med Assoc. 2009 Jun;107(6):403-5.
5
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.洛匹那韦-利托那韦单药治疗与洛匹那韦-利托那韦联合两种核苷类药物用于HIV维持治疗的96周分析。
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5.
6
Efficacy and tolerability of initial antiretroviral therapy: a systematic review.初始抗逆转录病毒疗法的疗效与耐受性：一项系统评价
AIDS. 2009 Jan 28;23(3):343-53; discussion 355-6. doi: 10.1097/QAD.0b013e32831db232.
7
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.在血浆病毒血症检测不到的HIV感染患者中用阿扎那韦替换洛匹那韦的疗效和安全性：SLOAT试验的最终结果
J Antimicrob Chemother. 2008 Jan;61(1):200-5. doi: 10.1093/jac/dkm413. Epub 2007 Nov 13.
8
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.在初治抗逆转录病毒治疗的患者中，阿扎那韦联合或不联合利托那韦作为每日一次高效抗逆转录病毒治疗方案一部分的疗效和安全性。
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7. doi: 10.1097/QAI.0b013e31815ace6a.
9
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.用于HIV-1感染初始治疗的三联与四联抗逆转录病毒疗法：一项随机对照试验
JAMA. 2006 Aug 16;296(7):769-81. doi: 10.1001/jama.296.7.769.
10
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.TRIZAL研究：从成功的高效抗逆转录病毒治疗转换为三协唯（阿巴卡韦-拉米夫定-齐多夫定复方片剂）：48周疗效、安全性及依从性结果
HIV Med. 2003 Apr;4(2):79-86. doi: 10.1046/j.1468-1293.2003.00139.x.
Zotero 插件